Placeholder Banner

BIO Comments on FDA's Guidance on Consultation Procedures: Foods Derived from New Plant Varieties

February 9, 2017

BIO submitted comments to the Food and Drug Administration (FDA) on its request for input on a public notice, Guidance on Consultation Procedures: Foods Derived from New Plant Varieties.

BIO applauds FDA’s work to develop and enforce a sensible, science-based approach to the regulation of products of agricultural biotechnology. FDA’s consultation process has worked well for nearly 30 years, and BIO members do not consider the current information requests to be unduly burdensome.

However, BIO strongly encourages the FDA to identify mechanisms to better incorporate its experience over time and, where possible, implement more efficient, streamlined review processes for products similar to ones the agency has reviewed in the past as well as products reviewed by the Center for Food Safety and Nutrition (CFSAN) and the Center for Veterinary Medicine (CVM).

Download Full Comments Below
BIO Comments On FDA ICR Final
Read the full comments letter here:
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…